H-Pro-Val-OtBu | 100690-03-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-Pro-Val-OtBu
• 英文别名: H-L-Pro-L-Val-O-t-Bu；H-Pro-Val-O^tBu
• CAS: 100690-03-7
• 化学式: C₁₄H₂₆N₂O₃
• 分子量: 270.372
• InChiKey: RDUCSQMNELHYQF-QWRGUYRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.22
• 重原子数：
  19.0
• 可旋转键数：
  4.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  67.43
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  H-Pro-Val-OtBu 在 哌啶 、 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 diphenylphosphorylazide 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 75.75h， 生成 cyclo-Asp(Pro-D-Pro-Val)-OBn
  参考文献：
  名称：

  Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors

  摘要：

  Selective inhibition of KDAC isoforms while maintaining potency remains a challenge. Using the largazole macrocyclic depsipeptide structure as a starting point for developing new KDACIs with increased selectivity, a combination of four different simplified largazole analogue (SLA) scaffolds with diverse zinc-binding groups (for a total of 60 compounds) were designed, synthesized, and evaluated against class I KDACs 1, 3, and 8, and class II KDAC6. Experimental evidence as well as molecular docking poses converged to establish the cyclic tetrapeptides (CTPs) as the primary determinant of both potency and selectivity by influencing the correct alignment of the zinc-binding group in the KDAC active site, providing a further basis for developing new KDACIs of higher isoform selectivity and potency.

  DOI：

  10.1021/acs.jmedchem.5b01632
• 作为产物：
  描述：

  L-缬氨酸叔丁酯盐酸盐 在 哌啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 生成 H-Pro-Val-OtBu
  参考文献：
  名称：

  Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors

  摘要：

  Selective inhibition of KDAC isoforms while maintaining potency remains a challenge. Using the largazole macrocyclic depsipeptide structure as a starting point for developing new KDACIs with increased selectivity, a combination of four different simplified largazole analogue (SLA) scaffolds with diverse zinc-binding groups (for a total of 60 compounds) were designed, synthesized, and evaluated against class I KDACs 1, 3, and 8, and class II KDAC6. Experimental evidence as well as molecular docking poses converged to establish the cyclic tetrapeptides (CTPs) as the primary determinant of both potency and selectivity by influencing the correct alignment of the zinc-binding group in the KDAC active site, providing a further basis for developing new KDACIs of higher isoform selectivity and potency.

  DOI：

  10.1021/acs.jmedchem.5b01632

文献信息

• [EN] CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS<br/>[FR] RÉACTIONS DE BORYLATION DÉCARBOXYLATIVE CATALYSÉES PAR CU ET NI
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2018175173A1

  公开（公告）日：2018-09-27

  The invention is directed to methods of converting a carboxylic acid group in a compound, via a redox active ester, to a corresponding boronic ester by treatment with bis(pinacolato)diboron-alkyllithium complex in the presence of a ligand, a Ni(ll) salt or a copper salt, and an Mg(ll) salt, in the presence of an alkyllithium or a lithium hydroxide or alkoxide salt. The product pinacolato boronate ester can be cleaved to provide a boronic acid. The invention is also directed to methods of preparing various compounds of medical value comprising boronic acid groups, and to novel boronic-acid containing compounds of medicinal value, including an atorvastatin boronic acid analog, a vancomycin aglycone boronic acid analog, and boronic acid containing elastase inhibitors mCBK319, mCBK320, mCBK323, and RPX-7009.

  这项发明涉及通过使用双(邻菲罗)二硼烷基锂络合物在配体、Ni(Ⅱ)盐或铜盐以及Mg(Ⅱ)盐的存在下，处理化合物中的羧酸基，通过氧化还原活性酯将其转化为相应的硼酯酯。在存在烷基锂或氢氧化锂或烷氧化锂盐的情况下，所述产品邻菲罗硼酸酯酯可以被裂解以提供硼酸。该发明还涉及制备含硼酸基的医用价值化合物的方法，以及具有药用价值的新型含硼酸基化合物，包括阿托伐他汀硼酸类似物、万古霉素裸核硼酸类似物和含硼酸的弹性蛋白酶抑制剂mCBK319、mCBK320、mCBK323和RPX-7009。
• Studies of Unusual Amino Acids and Their Peptides. XVII. The Synthesis of Peptides Containing<i>N</i>-Carboxymethyl Amino Acids. II
  作者：Toshifumi Miyazawa、Shin’ichi Hiramatsu、Yasuhiro Tsuboi、Takashi Yamada、Shigeru Kuwata

  DOI：10.1246/bcsj.58.1976

  日期：1985.7

  made up of three usual amino acid residues and one N-carboxymethyl (Cm-) amino acid residue. The application of vacuum distillation made the isolation of a Cm-amino acid diester more convenient and efficient compared with the chromatographic methods which had been used previously. The efficiency of peptide bond formation at the imino group of a Cm-amino acid by the acid chloride method was remarkably

  研究了由3个常用氨基酸残基和1个N-羧甲基(Cm-)氨基酸残基组成的4种四肽的合成路线。与以前使用的色谱方法相比，真空蒸馏的应用使 Cm-氨基酸二酯的分离更加方便和有效。在合适的反应条件下，酰氯法在Cm-氨基酸的亚氨基上形成肽键的效率得到显着提高。在C末端位置含有Cm-氨基酸的肽的肽链延伸中，偶联效率通常比仅由通常氨基酸残基组成的相应肽的情况差，并且取决于在耦合方法上非常重要，
• Peptidomimetics for Targeting Protein–Protein Interactions between DOT1L and MLL Oncofusion Proteins AF9 and ENL
  作者：Lei Du、Sierrah M. Grigsby、Aihong Yao、Yujie Chang、Garrett Johnson、Haiying Sun、Zaneta Nikolovska-Coleska

  DOI：10.1021/acsmedchemlett.8b00175

  日期：2018.9.13

  MLL-fusion proteins, AF9 and ENL, play an essential role in the recruitment of DOT1L and the H3K79 hypermethylation of MLL target genes, which is pivotal for leukemogenesis. Blocking these interactions may represent a novel therapeutic approach for MLL-rearranged leukemia. Based on the 7 mer DOT1L peptide, a class of peptidomimetics was designed. Compound 21 with modified middle residues, achieved significantly improved binding affinities to AF9 and ENL, with K-D values of 15 nM and 57 nM, respectively. Importantly, 21 recognizes and binds to the cellular AF9 protein and effectively inhibits the AF9-DOT1L interactions in cells. Modifications of the N- and C-termini of 21 resulted in 28 with 2-fold improved binding affinity to AF9 and much decreased peptidic characteristics. Our study provides a proof-of-concept for development of nonpeptidic compounds to inhibit DOT1L activity by targeting its recruitment and the interactions between DOT1L and MLL-oncofusion proteins AF9 and ENL.